Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Erasca, Inc. (NASDAQ:ERAS) have been given an average recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $20.1111.

ERAS has been the topic of several research reports. Wolfe Research set a $16.00 price objective on Erasca in a report on Thursday, June 4th. HC Wainwright boosted their target price on Erasca from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Bank of America upgraded Erasca from an “underperform” rating to a “neutral” rating and raised their price target for the company from $9.00 to $16.00 in a report on Thursday, June 4th. Citigroup reiterated a “buy” rating on shares of Erasca in a research report on Friday, March 13th. Finally, Guggenheim boosted their price objective on Erasca from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, March 16th.

Key Headlines Impacting Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest headlines.
• Neutral Sentiment: Multiple law firms, including Bernstein Liebhard, Rosen, Faruqi & Faruqi, Kahn Swick & Foti, and others, issued reminders about a pending securities class action and the August 10, 2026 lead-plaintiff deadline for investors who bought Erasca shares between January 14, 2025 and April 26, 2026. Article Title
• Neutral Sentiment: The lawsuits stem from allegations that investors were harmed after Erasca’s share price sharply fell amid concerns tied to a patient death, intellectual property questions, and a large market-cap loss, but the latest articles mainly repeat legal-notice language rather than provide new operational updates. Article Title
• Negative Sentiment: The accumulation of class action notices can weigh on sentiment because it raises overhang risk, potential legal costs, and uncertainty about future disclosures and liability for Erasca. Article Title

Insider Activity at Erasca

In related news, insider Ebun Garner sold 80,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $16.40, for a total value of $1,312,000.00. Following the transaction, the insider directly owned 25,076 shares in the company, valued at $411,246.40. This represents a 76.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 14.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Erasca

A number of institutional investors have recently bought and sold shares of the business. Neuberger Berman Group LLC lifted its stake in shares of Erasca by 11.3% in the 4th quarter. Neuberger Berman Group LLC now owns 12,358 shares of the company’s stock valued at $46,000 after purchasing an additional 1,253 shares during the period. Abel Hall LLC boosted its position in shares of Erasca by 8.1% in the 1st quarter. Abel Hall LLC now owns 16,947 shares of the company’s stock worth $274,000 after purchasing an additional 1,265 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Erasca by 77.8% during the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock worth $69,000 after purchasing an additional 1,859 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Erasca by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,787 shares of the company’s stock valued at $51,000 after purchasing an additional 2,820 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in Erasca by 11.1% in the fourth quarter. ProShare Advisors LLC now owns 44,216 shares of the company’s stock valued at $164,000 after purchasing an additional 4,430 shares during the last quarter. Institutional investors and hedge funds own 67.78% of the company’s stock.

Erasca Stock Down 0.1%

Shares of NASDAQ ERAS opened at $15.05 on Thursday. The firm’s 50-day simple moving average is $13.75 and its 200 day simple moving average is $11.65. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -16.18 and a beta of 0.73. Erasca has a 12-month low of $1.21 and a 12-month high of $24.28.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, equities analysts expect that Erasca will post -0.55 earnings per share for the current year.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.